QB3

NEW YORK (GenomeWeb News) — Mission Bio, a startup founded last year to commercialize PCR-activated cell sorting (PACS) technology developed at the University of California, San Francisco and the California Institute for Quantitative Biosciences (QB3), has been awarded a pair of National Institut

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

The expansion, which will quadruple the amount of incubator space that QB3 currently operates, is designed to quench the growing thirst of life science startups for incubator space at Mission Bay.

Approximately one year after Pfizer and the California Institute for Quantitative Biosciences inked a three-year, $9.5 million drug-discovery pact, the alliance is now overseeing seven projects combining scientists from various Pfizer sites and QB3-affiliated researchers at UC-San Francisco.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.